441 results on '"Focan C"'
Search Results
2. Determining clinically important differences in health-related quality of life in older patients with cancer undergoing chemotherapy or surgery
3. Patient management after primary rectal cancer diagnosis. Special focus on surgical treatment for non-metastatic disease.
4. Patient management after primary rectal cancer diagnosis. Special focus on surgical treatment for non-metastatic disease
5. End-of-life healthcare utilization in older patients with cancer: a large Belgian data linkage study
6. Palliative care at the end-of-life in older patients with cancer and associated age-related factors
7. Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV
8. Hospitalizations, emergency department visits and home care in older patients after cancer diagnosis: results from a large data linkage study with 3 year follow-up
9. A Belgian survey on geriatric assessment in oncology focusing on large-scale implementation and related barriers and facilitators
10. 1265MO Cause and place of death in older patients with cancer: Results from a large cohort study using linked clinical and population-based data
11. Sex moderates circadian chemotherapy effects on survival of patients with metastatic colorectal cancer: a meta-analysis
12. General practitioner contacts, hospitalizations, and nursing home transfers in older patients up to three years after new cancer diagnosis: Results from a large data linkage cohort study.
13. Rhythms in Tumor Markers
14. Geriatric screening and assessment among older patients with cancer: evaluation of long-term outcomes in a multicentric cohort of > 7, 000 patients
15. Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer
16. Dose response relationship with epirubicin in Neo-Adjuvant combination chemotherapy for advanced breast cancer. End results of a prospective randomized trial
17. Optimizing FOLFIRINOX tolerability in patients with colorectal cancer through dosing irinotecan in the morning for men and in the afternoon for women.
18. Considering temporal dimension for NSCLC medical management?
19. SIOG2022-0116 - Hospitalizations, emergency department visits and home care in older patients after cancer diagnosis: results from a large data linkage study with 3 year follow-up
20. First line infusion of 5-fluorouracil, leucovorin and oxaliplatin for metastatic colorectal cancer: 4-day chronomodulated (FFL4–10) versus 2-day FOLFOX2. A multicenter randomized Phase III trial of the Chronotherapy Group of the European Organization for Research and Treatment of Cancer (EORTC 05963): 3526
21. Phase II Trial of Chronomodulated Infusion of High-Dose Fluorouracil and l-Folinic Acid in Previously Untreated Patients With Metastatic Colorectal Cancer
22. The feasibility of classical cyclophosphamide, methotrexate, 5-fluorouracil (CMF) for pre- and post-menopausal node-positive breast cancer patients in a Belgian multicentric trial: a study of consistency in relative dose intensity (RDI) and cumulative doses across institutions
23. Phase I and pharmacokinetic study of weekly oral therapy with vinorelbine in patients with advanced breast cancer (ABC)
24. FINAL EFFICACY UPDATE AT 7 YEARS OF FLAT VS CHRONOMODULATED INFUSION (CHRONO) OF OXALIPLATIN, 5-FLUOROURACIL AND LEUCOVORIN AS FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER: Abstract 936 (Oral Presentation)
25. Phase III Multicenter Randomized Trial of Oxaliplatin Added to Chronomodulated Fluorouracil–Leucovorin as First-Line Treatment of Metastatic Colorectal Cancer
26. Is oral CMF a feasible adjuvant therapy in a multicenter trial for node positive (N+) breast cancer (BC) patients (pts)?
27. A phase III trial comparing full doses of epirubicin-cyclophosphamide (HEC) with intermediate doses (EC) and with CMF in the adjuvant therapy of node-positive (N+) breast cancer (BC) patients (PTS).
28. High-Dose Medroxyprogesterone Acetate as Adjuvant Hormonotherapy in Early Breast Cancer: 9 Years Results of a Multicenter Randomized Trial
29. The feasibility of classical cyclophosphamide, methotrexate, 5-fluorouracil (CMF) for pre- and post-menopausal node-positive breast cancer patients in a Belgian multicentric trial: a study of consistency in relative dose intensity (RDI) and cumulative doses across institutions
30. It's time for chronotherapy!
31. SIOG2023-5-P-342 - End-of-life healthcare utilization in older patients with cancer: a large Belgian data linkage study.
32. SIOG2021-0161 - Geriatric screening and assessment among older patients with cancer: evaluation of long-term outcomes in a multicentric cohort of > 7, 000 patients
33. Adherence to geriatric assessment-based recommendations in older patients with cancer: a multicenter prospective cohort study in Belgium.
34. Determining clinically important differences in health-related quality of life in older patients with cancer undergoing chemotherapy or surgery.
35. Experience of the Belgian Society of Medical Oncology with single-administration 5 g/m2 ifosfamide with mesna as second- or third-line therapy in advanced breast cancer
36. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years
37. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials
38. Determining clinically important differences in health-related quality of life in older patients with cancer undergoing chemotherapy or surgery
39. Adherence to geriatric assessment-based recommendations in older patients with cancer: a multicenter prospective cohort study in Belgium
40. Quality of life (QoL) in older patients (pts) with cancer and prognostic factors for QoL decline.
41. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials
42. Sex-related differences in circadian-dependent tolerance of Irinotecan (I) added to chronomodulated (chrono) 5-Fluorouracil (F), Leucovorin (L) and Oxaliplatin (O): Final results from international randomised time-finding study in patients with metastatic colorectal cancer (MCC)
43. Efficacy and tolerability of chronomodulated FOLFIRINOX (chronoIFLO) as 1st or 2nd line treatment in patients (pts) with metastatic colorectal cancer (MCC): Final results from an international trial (EORTC 05011)
44. Adherence to geriatric assessment (GA)-based recommendations in older patients (pts) with cancer.
45. Vitamin K epoxide reductase complex subunit 1 (VKORC1): A pharmacogenomic predictor of response and survival in patients (pts) on triplet hepatic artery infusion (HAI) and intravenous cetuximab (IV-Cet) for initially unresectable liver metastases from colorectal cancer (uLM-CRC) (EU trial OPTILIV).
46. Pharmacogenomic determinants of cetuximab and oxaliplatin pharmacokinetics during combined intravenous cetuximab (IV-Cet) and triplet hepatic artery chronomodulated infusion in patients (pts) with initially unresectable liver metastases from colorectal cancer (uLM-CRC) (EU OPTILIV trial).
47. SIOG2023-5-P-386 - Palliative care at the end-of-life in older patients with cancer and associated age-related factors.
48. Pharmacokinetics of a new anticancer drug, navelbine, in patients: Comparative study of radioimmunologic and radioactive determination methods
49. Sequential chemotherapy and circadian rhythm in human solid tumours: A randomised trial
50. Neurological toxicity of vindesine used in combination chemotherapy of 51 human solid tumors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.